Subscribe free

Upper Gastrointestinal Tract ·

Outcomes Similar for Immune Therapy After Nivolumab in Esophageal Cancer

First-line immune checkpoint inhibitor therapy for esophageal cancer recurrence shows no advantage based on prior adjuvant nivolumab treatment.

  • Among 81 patients, early tumor shrinkage rates were similar between those with and without prior nivolumab exposure.
  • No differences in progression-free survival (HR 1.4) or overall survival (HR 1.23), with 2-year overall survival at approximately 44%.

This suggests prior adjuvant immunotherapy does not hinder the effectiveness of subsequent treatments during recurrence.

Journal Article by Sugase T, Kanemura T (…) Miyata H et 17 al. in Ann Surg Oncol

© 2026. Society of Surgical Oncology.

read the whole article in Ann Surg Oncol

open it in PubMed

Summaries are written to help you decide what to read. They do not replace the full paper.

Free · 5 minutes a day

Get every new paper in Upper Gastrointestinal Tract.

Plus the Daily Selection: the five most relevant papers of the day, each cut to its key points.

Specialty newsletters: every new paper in your field, as a list of titles linked to the source. Daily Selection: the five that matter, cut to their key points.

FreeNo spamOne-click unsubscribe

More in Upper Gastrointestinal Tract

The latest stitches

Ann Surg Oncol2 Nov 2026

High symptom burden after oesophagectomy

On postoperative day 3, about one in five patients had high symptom burden, and the symptoms most linked to others differed between patient groups.

J Gastrointest Cancer23 Oct 2026

Uniportal esophagectomy linked to fewer pneumonias

In nine comparative studies of minimally invasive esophagectomy for esophageal cancer, uniportal VATS was associated with less pneumonia and a shorter stay than multiportal VATS—but the evidence is not strong enough to establish a preferred approach.

All papers in Upper Gastrointestinal Tract →